Sihui Zhu

Multidimensional analysis of tumour immune microenvironment in HCC: prognostic significance and implications for immunotherapy

J M Chen, Mingzhen Zhou, Wenyan Cao, Ziyan Zhou et autres

BACKGROUND: The combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic agents represents the standard first-line therapy for patients with unresectable hepatocellular carcinoma (HCC). However, most patients do not derive sustained clinical benefit. Emerging evidence has underscored a strong association between immunotherapy efficacy …

cn (code pays fourni par la source)

The safety and efficacy of in situ vaccine FOLactis for advanced hepatic malignancies

Ziyan Zhou, Xiaotong Lu, Lina Hu, Sihui Zhu et autres

cn (code pays fourni par la source)

Intracavitary infusion of FOLactis Lactobacillus leads to disappearance of MPE in patient with advanced lung adenocarcinoma

Mingzhen Zhou, Juan Zhang, Sihui Zhu, Yan Hong Zhao et autres

This case report presents the application of FOLactis, a lactic acid bacterium in situ vaccine, in the treatment of a lung adenocarcinoma patient who presented with malignant pleural effusion (MPE). An adult patient diagnosed with lung adenocarcinoma complicated by malignant pleural effusion …

cn (code pays fourni par la source)

Nomograms predicting benefit after immunotherapy in oral bifidobacteria supplementation ICC patients: a retrospective study

Sihui Zhu, Yuncheng Jin, Juan Zhang, Minzheng Zhou et autres

PURPOSE: The objective of this study was to develop nomograms for predicting outcomes following immunotherapy in patients diagnosed with intrahepatic cholangiocarcinoma (ICC). PATIENTS AND METHODS: A retrospective analysis was conducted on data from 75 ICC patients who received immunotherapy at Jinling Hospital …

cn (code pays fourni par la source)

KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer

Sihui Zhu, Yuncheng Jin, Mingzhen Zhou, Lin Li et autres

PURPOSE: There is mounting evidence that patients with liver cancer can benefit from Immune checkpoint inhibitors. However, due to the high cost and low efficacy, we aimed to explore new biomarkers for predicting the efficacy of immunotherapy. METHODS: Specimens and medical records …

cn (code pays fourni par la source)

An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy

Sihui Zhu, Chenxi Liu, Yunchen Jin, Hailong Zhang et autres

cn (code pays fourni par la source)

Nomograms predicting benefit after immunotherapy in oral bifidobacteria supplementation ICC patients: a retrospective study

Sihui Zhu, Yuncheng Jin, Juan Zhang, Minzheng Zhou et autres

Abstract Purpose: The objective of this study was to develop nomograms for predicting outcomes following immunotherapy in patients diagnosed with intrahepatic cholangiocarcinoma (ICC). Patients and Methods: A retrospective analysis was conducted on data from 75 ICC patients who received immunotherapy at Jinling …

in, cn (code pays fourni par la source)

Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy

Zhan Shi, Sihui Zhu, Yuncheng Jin, Qi Liang et autres

Background: Stereotactic body radiotherapy (SBRT) has emerged as an alternative approach for patients with hepatocellular carcinoma (HCC), and we aim to find potential prognostic biomarkers for HCC patients who received SBRT. Methods: In this study, we retrospectively analyzed HCC patients who underwent …

cn (code pays fourni par la source)

A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer

Mingzhen Zhou, Yuncheng Jin, Sihui Zhu, Xu Chen et autres

Abstract Objectives To assess the safety and efficacy of anlotinib (a multi‐targeted tyrosine kinase inhibitor) combined with toripalimab (a PD‐1 monoclonal antibody) in the treatment of unresectable biliary tract cancer (BTC). Methods In this prospective, single‐arm, single‐centre exploratory clinical study, patients with …

cn (code pays fourni par la source)

An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalised Immunotherapy and FGFR2 Inhibiter

Sihui Zhu, Chenxi Liu, Yunchen Jin, Hailong Zhang et autres

Abstract Advanced intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy which shows poor response to first-line treatments including radiotherapy, chemotherapy and targeted therapy. Its prognosis is extremely poor, with an overall survival of less than one year. Individualised neoantigen vaccines have shown …

cn (code pays fourni par la source)

Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors

Jie Shen, Jing Yan, Juan Du, Xiaoqin Li et autres

Introduction: Combination therapeutic mode is likely to be the key to enhance the efficacy of immunotherapy in a wider range of cancer patients. Herein, we conducted an open-label, single-arm, multicenter, phase II clinical trial that enrolled patients with advanced solid tumors who …

cn (code pays fourni par la source)

KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer

Sihui Zhu, Yuncheng Jin, Mingzhen Zhou, Lin Li et autres

Abstract Purpose There is mounting evidence that patients with liver cancer can benefit from Immune checkpoint inhibitors. However, due to the high cost and low efficacy, we aimed to explore new biomarkers for predicting the efficacy of immunotherapy. Methods Specimens and medical …

in, cn (code pays fourni par la source)